Buprenorfin etkileşimleri

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Alvimopan capsules are contraindicated in patients who have taken therapeutic doses of opioids for more than 7 consecutive days immediately prior to taking alvimopan capsules [see Warnings and Precautions ( 5.3 )]. (Alvimopan etiketi, Kontrendikasyonlar)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Examples: atazanavir, ritonavir Benzodiazepines : May increase buprenorphine-induced respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Opioid Antagonist: Naloxegol ↑ naloxegol Avoid use with BIXLENVO; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (Biktegravir, emtrisitabin ve tenofovir alafenamid etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Examples: butorphanol, nalbuphine, pentazocine Muscle Relaxants Clinical Impact: Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (Difenoksilat ve atropin etiketi, Kontrendikasyonlar)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: Rifampin, carbamazepine, phenytoin Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Examples: Rifampin, carbamazepine, phenytoin Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

BOXED WARNING Ketorolac tromethamine tablets, a nonsteroidal anti-inflammatory drug (NSAID), are indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. (Ketorolak etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (Levosetirizin etiketi, Uyarılar ve önlemler)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (Buprenorfin etiketi, İlaç etkileşimleri)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Examples: atazanavir, ritonavir Benzodiazepines : May increase buprenorphine-induced respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (Buprenorfin etiketi, İlaç etkileşimleri)

• Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (Metilnaltrekson etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: butorphanol, nalbuphine, pentazocine Muscle Relaxants Clinical Impact: Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists : Reversal of respiratory depression by partial agonists or mixed agonist/antagonists such as buprenorphine and pentazocine, may be incomplete. (Nalmefen etiketi, Uyarılar ve önlemler)

…concomitantly using strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) because these medications can significantly increase exposure to naloxegol which may precipitate opioid withdrawal symptoms such as hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)… (Naloksegol etiketi, Kontrendikasyonlar)

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists : Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists such as buprenorphine and pentazocine, may be incomplete. (Nalokson etiketi, Uyarılar ve önlemler)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

…Bulimia or anorexia nervosa, which increase the risk for seizure [see Warnings and Precautions (5.3) ] Chronic opioid or opiate agonist (e.g., methadone) or partial agonists (e.g., buprenorphine) use, or acute opiate withdrawal [see Warnings and Precautions (5.4) and Drug Interactions (7.2) ] Patients undergoing an abrupt discontinuation of alcohol, benzodiazepines,… (Naltrekson ve bupropion etiketi, Kontrendikasyonlar)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: atazanavir, ritonavir Benzodiazepines : May increase buprenorphine-induced respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (Olopatadin etiketi, Uyarılar ve önlemler)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (Olopatadin ve mometazon etiketi, Uyarılar ve önlemler)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: butorphanol, nalbuphine, pentazocine Muscle Relaxants Clinical Impact: Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: Rifampin, carbamazepine, phenytoin Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Examples: atazanavir, ritonavir Benzodiazepines : May increase buprenorphine-induced respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (Setirizin etiketi, Uyarılar ve önlemler)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (Siprofloksasin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (Buprenorfin etiketi, Kutulu uyarı)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (Allopurinol etiketi, Uyarılar ve önlemler)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (Aminofilin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Use with CNS depressants may result in an additive or potentiating effect. (Brimonidin etiketi, İlaç etkileşimleri)

Use with CNS depressants may result in an additive or potentiating effect. (Brimonidin ve timolol etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (Bupivakain etiketi, Uyarılar ve önlemler)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (Bupivakain ve adrenalin etiketi, Uyarılar ve önlemler)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (Desmopressin etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

MOTOFEN ® may potentiate the action of barbiturates, tranquilizers, narcotics, and alcohol. (Difenoksin ve atropin etiketi, İlaç etkileşimleri)

…in clinical decisions when prescribing BELBUCA to patients with risk factors such as hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia [see Dosage and Administration (2.4) , Adverse Reactions (6.1) , Clinical Pharmacology… (Buprenorfin etiketi, Uyarılar ve önlemler)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir) CYP3A4 Inducers Clinical Impact: The concomitant use of BELBUCA and CYP3A4 inducers can decrease the plasma concentration of buprenorphine [see Clinical Pharmacology (12.3) ] , potentially resulting in decreased efficacy or… (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir) CYP3A4 Inducers Clinical Impact: The concomitant use of BELBUCA and CYP3A4 inducers can decrease the plasma concentration of buprenorphine [see Clinical Pharmacology (12.3) ] , potentially resulting in decreased efficacy or… (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to clopidogrel. (Klopidogrel etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir) CYP3A4 Inducers Clinical Impact: The concomitant use of BELBUCA and CYP3A4 inducers can decrease the plasma concentration of buprenorphine [see Clinical Pharmacology (12.3) ] , potentially resulting in decreased efficacy or… (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (Lidokain ve adrenalin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Methadone Diphenylheptane opioids (e.g., methadone) have been shown in nonclinical studies to dose-dependently reduce the activation of ClC-2 by lubiprostone in the gastrointestinal tract. (Lubiproston etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (Metirozin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir) CYP3A4 Inducers Clinical Impact: The concomitant use of BELBUCA and CYP3A4 inducers can decrease the plasma concentration of buprenorphine [see Clinical Pharmacology (12.3) ] , potentially resulting in decreased efficacy or… (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

The interaction with high-dose fentanyl appears to be due to the combination of nifedipine and a beta-blocker, but the possibility that it may occur with nifedipine alone, with low doses of fentanyl, in other surgical procedures, or with other narcotic analgesics cannot be ruled out. (Nifedipin etiketi, Uyarılar)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Opioids: Decreased exposure to prasugrel. (Prasugrel etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Isoflurane and enflurane may also prolong the duration of action of initial and maintenance doses of Rocuronium Bromide Injection and decrease the average infusion requirement of Rocuronium Bromide Injection by 40% compared to opioid/nitrous oxide/oxygen anesthesia. (Rokuronyum etiketi, İlaç etkileşimleri)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (Teofilin etiketi, İlaç etkileşimleri)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (Trimetobenzamid etiketi, Uyarılar ve önlemler)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (Buprenorfin etiketi, Uyarılar ve önlemler)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase… (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase… (Buprenorfin etiketi, İlaç etkileşimleri)

Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (Dekstroamfetamin etiketi, İlaç etkileşimleri)

In Postanesthetic Use Doxapram is neither an antagonist to muscle relaxant drugs nor a specific narcotic antagonist. (Doksapram etiketi, Uyarılar)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Epoetin alfa etiketi, Uyarılar ve önlemler)

In RA, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents (NSAIDs), folic acid, corticosteroids and/or narcotics. (İnfliksimab etiketi, İlaç etkileşimleri)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (Lenalidomid etiketi, Uyarılar ve önlemler)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

Narcotics: Exacerbation of bradycardia possible. (Piridostigmin etiketi, İlaç etkileşimleri)

…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (Prazosin etiketi, İlaç etkileşimleri)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase… (Buprenorfin etiketi, İlaç etkileşimleri)

Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (Montelukast etiketi, İlaç etkileşimleri)